Cambridge, MA-based Aileron Therapeutics, a developer of peptide-based drugs, said today it gained exclusive rights to “click” chemistry from The Scripps Research Institute in La Jolla, CA. “Click chemistry describes synthetic chemistry tailored to generate substances quickly and reliably by joining (“clicking”) small reactive molecular building blocks together selectively and covalently to drive a spontaneous and irreversible binding reaction, a process that is inspired by natural chemistry,” the company and Scripps said in a press release. The press release did not provide financial details of the agreement. The Nobel laureate K. Barry Sharpless, a chemistry professor at Scripps Research, developed the technology involved in this agreement.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
